Results 241 to 250 of about 3,144,476 (264)

SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80‐K307

Biofactors, 2023
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide and is typically treated with the FOLFOX regimen (folinic acid, 5‐fluorouracil, and oxaliplatin). However, oxaliplatin resistance remains a serious clinical problem.
Dan Feng, Jinsong He, M. Yuan, Qing Chen, Xianqing Zeng, Qilin Zhou, Jian Wu, Bin Han   +7 more
semanticscholar   +1 more source

TWIST1 Promotes Colorectal Carcinoma Stemness and Oxaliplatin Resistance by Activating Microfibrillar-Associated Protein 2

Assay and drug development technologies, 2023
Colorectal carcinoma (CRC) is a fatal disease and ranks as the third most prevalent cancer globally. Stemness and drug resistance are the main causes of tumor recurrence in CRC.
Y. Liu, Minhan Chen, Bo Wu
semanticscholar   +1 more source

Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab

Clinical Cancer Research, 2007
AbstractPurpose: To establish whether cetuximab, a chimeric IgG1 antibody targeting epidermal growth factor receptor, has the potential to restore responsiveness to oxaliplatin in preclinical cancer models, as has been shown with irinotecan in irinotecan refractory metastatic colorectal cancer patients.Experimental Design: The effects of cetuximab and ...
Marie, Prewett, Dhanvanthri S, Deevi, Rajiv, Bassi, Fan, Fan, Lee M, Ellis, Daniel J, Hicklin, James R, Tonra   +6 more
openaire   +2 more sources

LSD1‐Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1‐Induced p62 Transcription in HCC

Hepatology, 2021
Oxaliplatin (OXA) is one of the most common chemotherapeutics in advanced hepatocellular carcinoma (HCC), the resistance of which poses a big challenge. Long noncoding RNAs (lncRNAs) play vital roles in chemoresistance.
Luyuan Ma, A. Xu, L. Kang, Rui Cong, Zhong-yi Fan, Xiang Zhu, Nan Huo, Wenpeng Liu, C. Xue, Q. Ji, Wenchao Li, Zhong Chu, Xiaofeng Kang, Ya-dong Wang, Zhijia Sun, Yuchen Han, Hanxiao Liu, Xiang Gao, Juqiang Han, Hua You, Caiyan Zhao, Xiaojie Xu   +21 more
semanticscholar   +1 more source

Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m6A of TRAF5 and Necroptosis in Colorectal Cancer.

Molecular Pharmaceutics, 2021
As a third-generation platinum drug, oxaliplatin (OX) is widely used as the first-line chemotherapeutic agent in the treatment of colorectal cancer (CRC). CRC cells acquire resistance to chemotherapy and develop resistance, which is a major challenge for
H. Lan, Yuyao Liu, Jinlong Liu, Xuanwei Wang, Zhonghai Guan, Jinlin Du, K. Jin   +6 more
semanticscholar   +1 more source

High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance

Apoptosis, 2023
Pyroptosis, as a type of inflammatory programmed cell death, has been studied in inflammatory diseases and numerous cancers but its role in pancreatic ductal adenocarcinoma (PDAC) remains further exploration.A TCGA-PDAC cohort was enrolled for bioinformatics analysis to investigate the effect of pyroptosis on the prognosis and drug sensitivity of ...
Guangfu, Wang, Jin, Chen, Shangnan, Dai, Jinfan, Zhang, Yong, Gao, Lingdi, Yin, Kuirong, Jiang, Yi, Miao, Zipeng, Lu   +8 more
openaire   +2 more sources

Txr1: an important factor in oxaliplatin resistance in gastric cancer

Medical Oncology, 2013
Oxaliplatin-based chemotherapy is the main treatment regimen for gastric cancer (GC), but can fail because of drug resistance. We investigated the role of a recently identified drug-resistance gene, taxol-resistant gene 1 (Txr1), in oxaliplatin resistance. A retrospective study based on banked tissue was carried out.
Jingtao, Bi, Zhigang, Bai, Xuemei, Ma, Jianning, Song, Yantong, Guo, Jingming, Zhao, Xin, Yi, Shiwei, Han, Zhongtao, Zhang   +8 more
openaire   +2 more sources

Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells

Archives of Pharmacal Research, 2021
Resolution to chemoresistance is a major challenge in patients with advanced-stage malignancies. Thus, identification of action points and elucidation of molecular mechanisms for chemoresist human cancer are necessary to overcome this challenge. In this study, we provide important evidence that kaempferol targeting RSKs might be a strategy to reduce ...
Juhee Park, Ga-Eun Lee, Hyung-Jung An, Cheol-Jung Lee, Eun Suh Cho, Han Chang Kang, Joo Young Lee, Hye Suk Lee, Jin-Sung Choi, Dae Joon Kim, Jong-Soon Choi, Yong-Yeon Cho   +11 more
openaire   +2 more sources

Cellular Resistance to Oxaliplatin and Drug Accumulation Defects

2009
Platinum drugs are employed in a wide range of solid tumors, and represent the mainstay of the first-line therapy of ovarian carcinoma. Although cisplatin has shown efficacy in the treatment of different types of tumors including ovarian carcinoma, resistance to treatment is a major limitation.
Laura Gatti, Paola Perego
openaire   +1 more source

Polyene phosphatidylcholine overcomes oxaliplatin resistance in human gastric cancer BGC823 cells

Biochemical and Biophysical Research Communications, 2018
Intrinsic or acquired resistance to oxaliplatin (L-OHP) is a major reason of treatment failure in gastric cancer and limits therapeutic success. Here we generated an oxaliplatin resistant gastric cancer cell line, BGC823/L-OHP, to investigate the effect of a hepatoprotective compound, polyene phosphatidylcholine (PPC), on conquest of oxaliplatin ...
Hongjun, Zhang, Hao, Song, Ronghui, Yuan, Xianxiang, Zhang, Hongsheng, Yu, Yuanyuan, Zhao, Tao, Jiang   +6 more
openaire   +2 more sources